NEW YORK (GenomeWeb News) — The Burnham Institute for Medical Research has inked an assay-development and license agreement with Johnson & Johnson Pharmaceutical Research and Development that will give the drug maker access to some of Burnham's high-throughput screening technologies to study drug targets for inflammatory diseases, Burnham said on Monday.

Burnham CEO John Reed said in a statement that he thinks the collaboration, which is the institute's first with a large pharma, "will foster the discovery of drug products with real clinical potential."